OneAlphaMed managed a 15-country, 85-expert asynchronous Delphi consensus process that produced internationally published treatment guidelines — in 14 weeks, without a single in-person meeting.
Industry / Specialty
Pharmaceutical & Healthcare
Scale / Audience
15,000+ HCPs
Core Solutions
Co-created Certification
Time to Value
Pan-India Deployment
Stop funding clicks. Start building undisputed credibility for your brand today.
A global pharmaceutical company supporting the development of international treatment guidelines for a complex hepatic condition needed to facilitate a rigorous, multi-round Delphi consensus process among 85 leading hepatologists and gastroenterologists across 15 countries. Traditional Delphi facilitation — requiring coordinated in-person meetings or complex live videoconference scheduling across multiple time zones — was logistically and financially prohibitive at this scale. OneAlphaMed designed and managed a purpose-built asynchronous digital Delphi platform that enabled all 85 experts to participate on their own schedules, with built-in anonymity controls, real-time consensus tracking, and structured moderation — producing a fully consensus-validated, internationally publishable guideline document in 14 weeks.
Producing internationally credible consensus guidelines requires extraordinary scientific rigour, complete process transparency, and the genuine engagement of the world's leading experts — at global scale.
Coordinating 85 senior clinicians across 15 countries and 8 time zones for a multi-round, structured consensus process is not a scheduling challenge — it is a logistical impossibility. Previous attempts to run international advisory processes of this scale had consistently resulted in low participation rates, inadequate representation from certain geographies, and compromise-driven rather than evidence-driven consensus outcomes.
A scientifically credible Delphi consensus process requires strict anonymity controls — ensuring that panelists cannot identify who has voted how on any statement until consensus is reached. This is trivially achievable in a controlled in-person setting with paper ballots, but extremely challenging to implement rigorously in a digital environment where communication patterns, response timing, and writing styles can inadvertently reveal identity.
Standard Delphi processes require multiple voting rounds — with revised statements and aggregated feedback between rounds — to move the panel from initial opinion distribution to genuine consensus. Sustaining expert engagement across 3-4 rounds over several months, with no geographic or social cohesion to motivate continued participation, is one of the most common failure modes in large-scale Delphi consensus initiatives.
OneAlphaMed built a purpose-designed digital facilitation platform that preserved all the methodological rigour of a formal Delphi process while making participation genuinely convenient for the world's busiest clinicians.
OneAlphaMed deployed a custom-built Delphi platform with end-to-end anonymization — ensuring that individual vote data was never accessible to any other panelist or to the facilitating team in identifiable form. Each expert was assigned a blinded participant code, and all inter-round reporting showed only aggregated vote distributions and representative anonymized comments, maintaining the integrity of the consensus process across all three voting rounds.
Rather than scheduling fixed live sessions, each Delphi round was structured as a 7-day asynchronous engagement window — during which panelists could log in at any time across any of the 8 time zones, review the current statement set, submit their votes and rationale comments, and review aggregated feedback from the previous round. Automated reminder sequences ensured high participation completion rates without requiring facilitator intervention.
OneAlphaMed's senior medical affairs team provided structured scientific moderation between rounds — synthesizing panelist comments, revising disputed statements based on expert feedback, and preparing clear inter-round summaries that helped panelists understand exactly where consensus was strong, where it was contested, and what the key scientific arguments on each side were. This active moderation was critical to moving the panel efficiently toward evidence-based consensus.
Rigorous Science, Without the Logistical Nightmare.
The core innovation was demonstrating that methodological rigor and logistical convenience are not in tension — they simply require purpose-built digital infrastructure. By designing the platform specifically for the requirements of a formal Delphi process rather than repurposing generic survey or meeting tools, OneAlphaMed created a facilitation environment where the world’s leading experts could contribute with the depth and care their scientific stature demanded, on schedules their clinical responsibilities required.
The asynchronous Delphi process produced internationally publishable guidelines in a fraction of the time typically required for a multi-country expert consensus initiative.
The consensus guidelines were published in a high-impact peer-reviewed journal, with the full methodological transparency of the Delphi process documented as a supplementary validation record.
Contributed to internationally significant clinical guideline development on their own schedule, without the time and travel costs of in-person attendance. Several panelists from lower-income countries who would have been logistically excluded from a conventional in-person process participated fully, meaningfully broadening the geographic and practice-setting diversity of the final guidelines.
Supported the generation of internationally credible, independently-authored clinical guidelines that provide the evidence-based prescribing framework within which their therapeutic product operates — without any promotional influence over the guidelines' content, and with the full scientific credibility that genuine expert independence guarantees.
Received a robust, transparently-generated, multi-country consensus guideline that reflected the genuine scientific views of the field's leading experts — not the logistical convenience of whoever happened to be able to attend a single in-person meeting. The guidelines have since been formally endorsed by three national specialty societies and are referenced in two country-specific formulary review documents.
The platform is built with a strict data separation architecture: individual vote records are stored in an encrypted, access-controlled database accessible only to the platform's technical administrator — not to the scientific facilitators. All inter-round reporting is generated programmatically from aggregated data, with a minimum reporting threshold (no comment is attributed if fewer than 5 panelists share a similar view) to prevent identity inference from comment content or writing style.
The platform tracks engagement at the panelist level, with automated escalation protocols for non-engagement: a reminder message at Day 3, a personal email from the scientific chair at Day 5, and a phone call from the project coordinator at Day 6. Our experience across multiple Delphi processes is that the 7-day asynchronous window reduces dropout rates significantly compared to scheduled live sessions, as it accommodates clinical emergencies, travel, and other scheduling conflicts that would otherwise cause a panelist to miss an entire round.
Yes, under the appropriate governance structure. OneAlphaMed's role is facilitation, not scientific direction — we manage the process, not the content. The scientific chair and steering committee are independent clinicians with full editorial authority over all statement development, revision, and final wording. The pharmaceutical sponsor's involvement is disclosed as logistical and financial facilitation support, with a formal firewall preventing commercial team access to any aspect of the scientific consensus process.
+91 9811660635
info@onealphamed.com
2414, Ground Floor, Aravali Vihar, Sector 49 Faridabad, Haryana – 121001 India
Copyright © 2026 OneAlphaMed. All Rights Reserved.